US stocks surged | Plan to globally launch oral weight loss drug Orforglipron next year Eli Lilly (LLY.US) soared 4% at one point

According to the Securities Times app, on Tuesday, the stock price of Eli Lilly (LLY.US) rose by 4% at one point, and as of the time of publication, the stock had risen by over 3%, reaching $718.74. In terms of news, the company announced that its daily oral weight loss drug Orforglipron had successfully achieved its main research goal in a late-stage clinical trial for obese and type 2 diabetes patients, and plans to launch the drug globally next year. In the 72-week study, patients receiving the highest dose of Orforglipron lost an average of 10.5% of their weight, while the placebo group lost 2.2%.